Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 16/20 | 1.00 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062537 | 0.98 | CHKA (1.00) | CHKACHKBALDH1A1LMNAHTT | |
| SCHEMBL16378602 | 0.93 | CHKA (0.90) | CHKACHKBALDH1A1LMNAHTT | |
| SCHEMBL10062535 | 0.91 | CHKA (0.96) | CHKACHKBALDH1A1LMNAHTT | |
| SCHEMBL17190307 | 0.80 | CHKA (0.76) | CHKACHKBALDH1A1LMNAHTT | |
| SCHEMBL13851327 | 0.80 | CHKA (0.71) | CHKACHKBALDH1A1LMNAHTT | |
| SCHEMBL1108048 | 0.79 | CHKA (1.00) | CHKAALDH1A1LMNAHTTSMN1; SMN2 | |
| Bromide SCHEMBL17961956 | 0.78 | CHKA (0.68) | CHKACHKBALDH1A1LMNAHTT | |
| Bromide SCHEMBL17961946 | 0.78 | CHKA (0.68) | CHKACHKBALDH1A1LMNAHTT | |
| Bromide SCHEMBL30432580 | 0.78 | CHKA (1.00) | CHKACHKBALDH1A1LMNAHTT | |
| Bromide SCHEMBL17961991 | 0.78 | CHKA (0.68) | CHKACHKBALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012706-A | Application of DHODH-CHK alpha-TRIM 28 in screening medicines for inhibiting proliferation or growth of colorectal cancer cells | 山西医科大学 | 2026-05-12 | — | — | CN | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| CN-118831161-A | Use of ETNK expression inhibitor in preparation of medicine for treating breast cancer | 武汉大学中南医院 | 2024-10-25 | — | — | CN | claimed |
| WO-2023144357-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | UNIVERSITE PARIS CITE (FR) | 2023-08-03 | — | — | WO | claimed |
| EP-4219764-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2023-08-02 | — | — | EP | claimed |
| CN-122012706-A | Application of DHODH-CHK alpha-TRIM 28 in screening medicines for inhibiting proliferation or growth of colorectal cancer cells | 山西医科大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-122012706-A | Application of DHODH-CHK alpha-TRIM 28 in screening medicines for inhibiting proliferation or growth of colorectal cancer cells | 山西医科大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12458659-B2 | Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| CN-119530371-A | Application of FOXO3a expression inhibitor in preparation of medicine for treating acute brain injury after subarachnoid hemorrhage | 武汉大学人民医院（湖北省人民医院） | 2025-02-28 | — | — | CN | disclosed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | disclosed |
| CN-118831161-A | Use of ETNK expression inhibitor in preparation of medicine for treating breast cancer | 武汉大学中南医院 | 2024-10-25 | — | — | CN | disclosed |
| CN-118831161-A | Use of ETNK expression inhibitor in preparation of medicine for treating breast cancer | 武汉大学中南医院 | 2024-10-25 | — | — | CN | disclosed |
| US-20240299589-A1 | DIAGNOSING AND TREATING CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-09-12 | — | — | US | disclosed |
| US-11813338-B2 | Diagnosing and treating cancer | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116531414-A | Application of saccharomycete for covering membrane of sacculus in preparing medicine for treating and/or improving colon cancer | 南京大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023144357-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | UNIVERSITE PARIS CITE (FR) | 2023-08-03 | — | — | WO | disclosed |
| EP-4219764-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20220133770-A1 | METHODS FOR TREATING MACROPHAGE-MEDIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFORE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299589-A1 | DIAGNOSING AND TREATING CANCER | CHKA, CHKB, CILK1 | CHKA 1/4885CHKB 2/4885ALDH1A1 1793/4885 |
| US-11813338-B2 | Diagnosing and treating cancer | CHKA, CHKB, CILK1 | CHKA 1/4885CHKB 2/4885ALDH1A1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.